




## Article

# Development, Evaluation, and Molecular Docking of Oral Dissolving Film of Atenolol

Karina Citra Rani <sup>1</sup>, Nani Parfati <sup>1</sup>, Ni Luh Dewi Aryani <sup>1</sup>, Agnes Nuniek Winantari <sup>1</sup>, Endang Wahyu Fitriani <sup>1</sup>, Aditya Trias Pradana <sup>1,2</sup>, Roisah Nawatila <sup>1</sup>, Astridani Rizky Putranti <sup>1</sup>, Florencia Irine <sup>1</sup>, Florentia Angelica <sup>1</sup>, Cintya Yohanes <sup>1</sup> and Christina Avanti <sup>1,\*</sup>

<sup>1</sup> Department of Pharmaceutics, Faculty of Pharmacy, University of Surabaya, Surabaya 60293, Indonesia; karinacitrarani@staff.ubaya.ac.id (K.C.R.); nani\_parfati@staff.ubaya.ac.id (N.P.); dewi\_aryani@staff.ubaya.ac.id (N.L.D.A.); agnes\_nuniek@staff.ubaya.ac.id (A.N.W.); endangwahyu@staff.ubaya.ac.id (E.W.F.); aditya\_trias@staff.ubaya.ac.id (A.T.P.); roisah@staff.ubaya.ac.id (R.N.); astridaniputranti@staff.ubaya.ac.id (A.R.P.); florenirine21@gmail.com (F.I.); florentiaangelica@gmail.com (F.A.); cintya.yohanes@yahoo.co.id (C.Y.)

<sup>2</sup> Department of Pharmaceutics and Industrial Pharmacy, Faculty of Pharmaceutical Sciences, Chulalongkorn University, Bangkok 10330, Thailand

\* Correspondence: c\_avanti@staff.ubaya.ac.id; Tel.: +62-31-298-1000

**Abstract:** The development of oral dissolving film (ODF) of atenolol is an attempt to enhance convenience and compliance for geriatric patients suffering from hypertension. Film former is the most essential component in ODF that determines the physical characteristic and drug release. In this study, three different types of film former including HPMC E5 4% (*w/v*), 5% (*w/v*), CMC-Na 3% (*w/v*), 4% (*w/v*), and Na-alginate 2.5% (*w/v*), 3% (*w/v*) were optimized in Formula 1 (F1) to Formula 6 (F6), respectively. A solvent casting method was employed to develop ODF of atenolol. The films formed by HPMC E5 produced a smooth and flexible surface, whereas CMC-Na and Na-alginate produced gritty textured films. Satisfactory results were obtained from several physical parameters such as film thickness, folding endurance, swelling index, and disintegration time. The homogeneity, drug content, and dissolution properties of ODF with HPMC exhibited better characteristics than the other formulas. Formula 1 exhibited the highest drug release compared to the other ODFs. The molecular docking results showed that there was a hydrogen bonding between atenolol and film formers which was also supported by the FTIR spectrum. The findings of this study suggest that HPMC E5 is the most favorable film former for ODF of atenolol.

**Keywords:** oral dissolving film; atenolol; HPMC E5; CMC-Na; Na-alginate



**Citation:** Rani, K.C.; Parfati, N.; Aryani, N.L.D.; Winantari, A.N.; Fitriani, E.W.; Pradana, A.T.; Nawatila, R.; Putranti, A.R.; Irine, F.; Angelica, F.; et al. Development, Evaluation, and Molecular Docking of Oral Dissolving Film of Atenolol. *Pharmaceutics* **2021**, *13*, 1727. <https://doi.org/10.3390/pharmaceutics13101727>

Academic Editors: J. Carolina Visser and Herman Woerdenbag

Received: 30 August 2021

Accepted: 14 October 2021

Published: 19 October 2021

**Publisher's Note:** MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.



**Copyright:** © 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<https://creativecommons.org/licenses/by/4.0/>).

## 1. Introduction

The most preferred route for drug administration is the oral route. The development of an innovative drug delivery system to enhance patient convenience and compliance is needed. Oral dissolving film (ODF) is an invention to provide convenience to patients, especially for geriatric patients suffering from dysphagia [1]. ODF is stable in the solid film-form but easily disintegrated upon contact with saliva in the oral cavity. This dosage form does not require water for administration and gives quick absorption [2]. ODF also provides another advantage for highly permeable drugs of which the first-pass effect is significant for those drugs [3]. Formulation of these drugs in ODF facilitates the drug release through the buccal mucosa for direct absorption. This mechanism can reduce the extent of the first-pass effect and food interactions during the absorption process [4]. ODF may also exhibit a faster pharmacological response due to the faster disintegration, dissolution, and trans-mucosal absorption process [5].

Atenolol is an antihypertension drug with a relatively polar hydrophilic compound and a water solubility of 26.5 mg/mL. The oral bioavailability of atenolol is approximately

45–55%, due to the first-pass effect mechanism [5]. This drug is also widely prescribed as first-step therapy for hypertension in geriatric patients who have difficulty swallowing. Therefore, the development of ODF atenolol is a promising strategy to enhance the convenience and therapeutic efficacy of atenolol. Hence, the present study aims to formulate oral dissolving films of atenolol that produce desired physical and drug release characteristics. The most essential component for ODF preparation is a polymer, which serves as a film former. The type and concentration of film formers influence the robustness, disintegration, and drug release characteristics of ODF [3]. Various hydrophilic polymers that facilitate rapid dissolution, desirable mechanical properties, good mouthfeel properties, and low water vapor absorption are suitable candidates for a film former [6].

Hydroxypropyl methylcellulose (HPMC) E5, carboxymethyl cellulose sodium (CMC-Na), and sodium alginate (Na-alginate) are several polymers that have film-forming abilities [7]. HPMC E5 revealed excellent flexibility and uniformity in the development of ODF. Moreover, HPMC E5 promotes the dissolution rate of flupentixol, which is incorporated in these films [8]. CMC-Na also exhibits suitable characteristics of oral thin film development. The study of probiotic dissolving films to prevent dental caries was conducted using CMC-Na as film former. The obtained oral thin film is characterized as a uniform film with excellent thickness, dissolving time, hygroscopicity, and biotherapeutic properties [9]. Films with a 2–5% *w/v* concentration of both polymers (HPMC E5 and CMC-Na) are clear, transparent, and of preferable mechanical characteristics [8]. Sodium alginate also served as a desirable film former which promotes drug release through swelling mechanism [10]. Sodium alginate also has good film properties and is non-sticky when applied as film former [11]. The concentration of sodium alginate in film formulation was 1.5–3% *w/v* [12].

In this study, three different types of film former (HPMC E5, CMC-Na, and Na-alginate) were optimized to produce ODFs and six formulas of HPMC E5 4% (*w/v*) (F1); HPMC E5 5% (*w/v*) (F2); CMC-Na 3% (*w/v*) (F3); CMC-Na 4% (*w/v*) (F4); Na-alginate 2.5% (*w/v*) (F5); Na-alginate 3% (*w/v*) (F6) were developed. All six formulas were chosen based on our preliminary study to find an optimum gel former concentration that produced ODF with acceptable characteristics, such as being thin, flexible, and having adequate mechanical properties. The solvent casting method was used to develop all of these formulas as the method is the most visible method in the optimization study of pharmaceutical ODF. In fact, this method can be easily applied, and sophisticated equipment is not required. All of the film components were suspended or dissolved in water, then the dispersion or solution was quickly cast and dried to produce a film [12]. The effect of film former type and concentration were evaluated to the physical characteristics of ODFs such as film thickness, folding endurance, swelling index, and disintegration time [11]. Drug content and *in vitro* drug dissolution were also compared among these formulas [13]. IR spectrum study and molecular docking were also conducted to analyze the interaction between atenolol and film former. Morphological characteristic of ODFs was also observed using a scanning electron microscope. Those evaluations were conducted to obtain the most desirable ODF of atenolol.

## 2. Materials and Methods

### 2.1. Materials

Atenolol and Poloxamer 188 were kindly supplied by PT. Kalbe Farma Tbk. by stating that Atenolol pharmaceutical grade was purchased from Refarmed Chemicals Ltd. (Lugano, Switzerland) and Poloxamer 188 pharmaceutical grade was purchased from BASF Corporation (Ludwigshafen, Germany). Hydroxypropyl methyl cellulose (HPMC) E5 pharmaceutical grade was purchased from Wuhan Senwayer Century Chemical Co., Ltd. (Wuhan, China). Sodium carboxymethyl cellulose (CMC-Na) pharmaceutical grade was purchased from Handan Yaxiang Chemical (Handan, China), Sodium alginate (Na-alginate) pharmaceutical grade (I-3 type) was purchased from Kimica Corporation (Tokyo, Japan). Glycerin pharmaceutical grade was purchased from PT. Wilmar Nabati Indonesia (Gresik, Indonesia). Citric acid, potassium acesulfame, methyl paraben, and orange flavor

pharmaceutical grade were purchased from Merck and Co. Inc. (Kenilworth, IL, USA). Propylene glycol pharmaceutical grade was purchased from Shell Chemicals (The Hague, The Netherlands). All other chemicals were of analytical grade such as sodium dihydrogen phosphate was purchased from Merck KGaA (Darmstadt, Germany), disodium hydrogen phosphate was purchased from Merck KGaA (Darmstadt, Germany), dibutylamine was purchased from Merck KGaA (Darmstadt, Germany), glacial acetic acid was purchased from Merck KGaA (Darmstadt, Germany), and sodium 1-heptane sulfonate was purchased from Tokyo Chemical Industry Co. Ltd. (Tokyo, Japan).

## 2.2. Methods

### 2.2.1. Sample Preparation

Three different types of film former include HPMC E5 4%, 5% (*w/v*); CMC-Na 3%, 4% (*w/v*); and Na-alginate 2.5%, 3% (*w/v*) were optimized in Formula 1 (F1) to Formula 6 (F6), respectively, as exhibited in Table 1. The solvent casting method was used to develop ODF of atenolol.

**Table 1.** Composition of different film casting solutions.

Component	F1 HPMC E5 4% (mg)	F2 HPMC E5 5% (mg)	F3 CMC-Na 3% (mg)	F4 CMC-Na 4% (mg)	F5 Na-Alginate 2.5% (mg)	F6 Na-Alginate 3% (mg)
Atenolol	25	25	25	25	25	25
HPMC E5	40	50	-	-	-	-
CMC-Na	-	-	30	40	-	-
Na-Alginate	-	-	-	-	25	30
Glycerin	8	10	3	4	2.5	3
Poloxamer 188	0.3	0.3	0.3	0.3	0.3	0.3
Citric Acid	2	2	2	2	2	2
Potassium Acesulfame	3	3	3	3	3	3
Methyl Paraben	0.05	0.05	0.05	0.05	0.05	0.05
Orange Flavor	1	1	1	1	1	1
Sunset Yellow FDC	0.01	0.01	0.01	0.01	0.01	0.01
Propylene Glycol	2	2	2	2	2	2
Purified Water	1 mL	1 mL	1 mL	1 mL	1 mL	1 mL
Total Weight of ODF	81.36	93.36	66.36	77.36	60.86	66.36

Note: HPMC E5 (hydroxypropyl methyl cellulose type E5), CMC-Na (sodium carboxymethyl cellulose), Na-Alginate (sodium alginate) were expressed as a percentage of purified water (*%w/v*). Each of these formulas was prepared for 1 film.

A polymeric solution was prepared by dissolving the film-former polymer in a specific proportion in an excipient mixture consisting of potassium acesulfame, citric acid, poloxamer 188, orange flavor, and sunset yellow FDC in purified water and methyl paraben in propylene glycol. This mixture was maintained at 2–2.5 h. After that, glycerin was added to the atenolol powder so that it could be wetted. Then, this solid mixture was added to the polymeric solution gradually and stirred for 45 min at 800 rpm and then left until the air bubbles disappeared (without sonication). The solution was cast onto an acrylic plate (18 × 18 cm) and then dried at 50 ± 2 °C for 15 h. The resultant film was cut to a size of 2 × 3 cm, in which 25 mg of atenolol was included. Films having air bubbles, cuts, or imperfections were excluded from the study. The next step is to evaluate the films.

### 2.2.2. Film Thickness

The thickness of the film was normally measured at five different locations of the films using a micrometer screw gauge. The standard deviation and mean value were then calculated. The ideal film thickness ranges from 50–1000  $\mu\text{m}$  [14]. The other study also posits that ODF thickness below 0.3 mm is still acceptable [15].

### 2.2.3. Folding Endurance

To determine the folding endurance, a strip of film was repeatedly folded at an angle of  $180^\circ$  at the same place until it broke. Films with a folding endurance value of 300 or more are considered to be ideal [14]. A higher folding endurance value signifies the more mechanical strength of the film [16].

### 2.2.4. Swelling Index

A simulated saliva solution was used to check the swelling studies of films. This method required a petri dish, plate glass, and digital analytic scale where the film was then weighed and immersed into simulated saliva solution (phosphate buffer pH 6.8). An increase in the weight of the film is noted as constant predetermined time intervals until no more increase in weight [16]. Then, the swelling index can be determined by these parameters:

$$\text{Swelling index} = \frac{w_t - w_0}{w_0}$$

$w_t$  = weight of film at time interval  $t$  (final weight)

$w_0$  = weight of film at time 0 (initial weight).

### 2.2.5. Determination of Disintegration Time

The disintegration time test was conducted manually by placing the film into a 10 mL simulated saliva solution (phosphate buffer pH 6.8) in a beaker glass and stirred continuously every 10 s. The time required for the film to dissolve completely is considered as the disintegration time. Ideally, the disintegration time for an ODF ranges from 5–30 s, though disintegration within 60 s is acceptable [16].

### 2.2.6. Weight Uniformity

The weight uniformity test was carried out by weighing 20 units of ODF at a size of  $2 \times 3$  cm. The weight of the ODF were tabulated and the results were expressed as the average weight  $\pm$  SD.

### 2.2.7. Drug Content

The drug content in a film is determined by a standard assay method specified for individual drug in different pharmacopoeia. ODF was dissolved with 50 mL mobile phases in a glass beaker and sonicated for 5 min. The dissolved film was taken into a 100 mL volumetric flask and dissolved in mobile phase (100 mL). Then, 5 mL of this solution was taken into a 50 mL volumetric flask and dissolved in the mobile phase (50 mL). Afterward, it was filtered using a  $0.5 \mu\text{m}$  membrane filter, and the drug content was observed using the UPLC H Class Waters (Milford, MA, USA), equipped with Empower 3 software as data system [17]. The stationary phase used was Acquity UPLC BEH C18  $1.7 \mu\text{m}$  ( $2.1 \times 50$  mm column) and the detector was a UV detector.

Preparation of the mobile phase was used 1.1 g of sodium 1-heptansulfonate and 0.71 g of sodium phosphate and dissolved in 700 mL of purified water. Then, 2 mL of dibutyl amine and phosphoric acid 0.8 M were added to the mixture until it reached pH 3.0. Finally, 300 mL methanol was added to the mixture. Then, it was filtered using a  $0.5 \mu\text{m}$  membrane filter [17]. The flow rate for the mobile phase was 0.3 mL/min.

### 2.2.8. In Vitro Drug Dissolution

In vitro drug dissolution study ( $n = 4$ ) were performed utilizing a Hanson SR8-Plus dissolution test system (Hanson Research Co., Chatsworth, CA, USA) according to USP 40 apparatus 5, paddle over disk method. The dissolution medium used was 900 mL of acetate buffer pH 4.6. The temperature was maintained at  $37 \pm 0.5$  °C and rotation speed of 50 rpm was repeatedly adjusted. Sample of drug dissolved was collected at predetermined intervals and was determined by using the ULPC method [17].

### 2.2.9. Surface pH

Surface pH was determined to evaluate the acceptability of the ODF administration in the oral cavity. ODF was placed in a petri dish, then wetted by using 0.5 mL purified water for 60 s. The pH of ODF was measured by touching a pH meter (Schott pH meter LAB 850, Mainz, Germany) electrode of with the ODF surface. The surface pH of ODF should be within the normal range of salivary pH 6.8–7.4 [5].

### 2.2.10. Film Morphology Using Scanning Electron Microscope (SEM)

Morphological analysis of the film was performed using a scanning electron microscope (Hitachi High Technologies America, Inc., Schaumburg, IL, USA). The film was directly fixed on a metal stub using double side adhesive tape. Samples were gold-coated at 10 mA for 20 s. Surface morphology can be obtained at 15 kV and 5 kV, respectively at 1000 and 5000 times magnification [18].

### 2.2.11. IR Spectrum Study

Fourier transform infrared (FT-IR) studies were carried out to analyze the possible drug-excipient interaction. The FT-IR spectrum of pure drug, film former, and extruded films were recorded using an FT-IR spectrometer (Shimadzu FT-IR 4200, Kyoto, Japan) over a scan range from 4000 to  $400 \text{ cm}^{-1}$ . The FT-IR spectrum of the atenolol (pure drug), film former (HPMC, CMC-Na, and Na-alginate), and oral dissolving films were compared to determine drug-excipient interaction, especially film former [10].

### 2.2.12. Molecular Docking Study

The two and three-dimensional (3-D) structures of atenolol and film-forming agents were constructed using MarvinSketch program version 19.20 software (ForOSX), ChemAxon Ltd., Budapest, Hungary. Similar software was utilized for energy minimization of structures of the molecules. Prior to the study, the International Union of Pure and Applied Chemistry (IUPAC) name and the chemical structure of atenolol and film-forming agents were confirmed using PubChem<sup>®</sup>. The interactions between atenolol and film-forming agents were determined in silico by molecular docking using Autodock 4.2 software. The grid box covered all the molecules and spacing (Armstrong) was 0.375. The free binding energy ( $\Delta G$ ) in silico of atenolol-sodium alginate, atenolol-CMC Na, and atenolol-HPMC, were obtained after running 100 times of the molecular docking by Autodock 4.2. The bondings and the interactions distances between atenolol and film-forming agents. The Discovery Studio Visualizer (DSV), Biovia, Dassault system, San Diego, CA, USA) was utilized for visualizing the bonding and the interactions distances between atenolol and film-forming agents.


### 2.2.13. Data Analysis

The results of physical characteristics evaluation such as folding endurance, swelling index, and in vitro drug dissolution were analyzed using one-way ANOVA ( $p < 0.05$ ). Other parameters including film thickness, weight uniformity, drug content, and surface pH were analyzed by comparing the results to the specified requirements.

### 3. Results

#### 3.1. Visual Appearance

The visual observation results of the six ODF formulas are shown in Figure 1. From the organoleptic results, it can be seen that the majority of the formulas exhibited flexible film with a smooth surface. However, the ODF formulated from CMC-Na as a film former formed a gritty texture. Other organoleptic results were sweet with slightly bitter taste without any odor.



**Figure 1.** Physical appearance of the ODF. (a) F1 with 4% HPMC E5; (b) F2 with 5% HPMC E5; (c) F3 with 3% CMC-Na; (d) F4 with 4% CMC-Na; (e) F5 with 2.5% Na-alginate; and (f) F6 with 3% Na-alginate.

#### 3.2. Film Thickness

Table 2 shows that HPMC E5 produced a higher film thickness compared to CMC-Na and Na-alginate. However, all of the film formers keep exhibited suitable film thickness of oral dissolving films.


**Table 2.** Orally dissolving film thickness.

Parameter	F1	F2	F3	F4	F5	F6
Film thickness (mm)	$0.233 \pm 0.031$	$0.228 \pm 0.040$	$0.185 \pm 0.001$	$0.206 \pm 0.002$	$0.116 \pm 0.006$	$0.136 \pm 0.008$

The results were expressed as mean  $\pm$  SD,  $n = 4$ .

#### 3.3. Folding Endurance


Observations of endurance on the folding process in the six formulas are presented in Figure 2. The ODF of atenolol formula using HPMC E5 and CMC-Na met the folding endurance requirement of ODF (>300 times), where F1 and F2 obtain excellent value. However, ODF prepared from Na-alginate produced a brittle film and exhibited a low value of endurance.



**Figure 2.** Folding endurance in times of the ODFs (mean  $\pm$  SD,  $n = 4$ ). The (\*) indicates a significant different among similar polymer type groups ( $p < 0.05$ ); the (#) indicates a significant different between different polymer type groups ( $p < 0.05$ ); and the (ns) indicates a non-significant different ( $p > 0.05$ ).

### 3.4. Swelling Index

The swelling index of ODF formulated with CMC-Na showed a significant value compared to the other two film formers, as seen in Figure 3. However, the increased concentration of each film former did not show a significant difference to the swelling index of the dosage forms.



**Figure 3.** Swelling index of ODFs in simulated saliva solution (mean  $\pm$  SD,  $n = 4$ ). The (\*) indicates a significant different among similar polymer type groups ( $p < 0.05$ ); the (#) indicates a significant different between different polymer type groups ( $p < 0.05$ ); and the (ns) indicates a non-significant different ( $p > 0.05$ ).

### 3.5. Disintegration Time

Table 3 shows the disintegration time of the ODF in simulated saliva solution (phosphate buffer pH 6.8). F5 and F6 show significantly faster disintegration times compared to the other four formulas. Increasing the concentration of the film former also increases the time needed for ODF to disintegrate.


**Table 3.** Disintegration time of ODFs.

Parameter	F1	F2	F3	F4	F5	F6
Disintegration time (second)	31.99 ± 1.60	42.11 ± 0.57	40.47 ± 0.04	50.46 ± 0.09	13.26 ± 0.11	14.47 ± 0.28

The results were expressed as mean ± SD,  $n = 4$ .

### 3.6. Weight Uniformity


It can be seen in Figure 4 that an increase in the concentration of the film former in the formula resulted in an increase in the weight of the formulated ODF. Furthermore, each prepared formula resulted in a good uniformity of weight with a low deviation between manufacturing replications.



**Figure 4.** Oral dissolving films weight (mean ± SD,  $n = 4$ ).

### 3.7. Drug Content

Atenolol content in ODF was measured by UPLC. The results of these observations can be seen in Figure 5, where the drug content is quite large in all formulas. The highest drug content is in Formula 3 with 3% CMC-Na as the film former, while the lowest was in Formula 6 with 3% Na-Alginate as the film former.




**Figure 5.** Atenolol content in oral dissolving films measured by UPLC method.



### 3.8. In-Vitro Drug Dissolution


The atenolol dissolution rate of ODFs was carried out in a 4.6 pH acetate buffer medium. Samples were taken after 30 min, and the amount of drug dissolved is shown in Figure 6. F1 and F2 (formulated from HPMC E5 as the film former) showed the highest percentage of drug dissolved. Meanwhile, increasing the concentration of the film former also decreases the dissolution rate of atenolol from ODFs.



**Figure 6.** Percentage of atenolol dissolved from ODFs within 30 min of the dissolution test (mean  $\pm$  SD,  $n = 4$ ). The (#) indicates a significant different between various polymer type groups ( $p < 0.05$ ); The (ns) indicates no significant different ( $p > 0.05$ ).

### 3.9. Surface pH


The surface pH of the films must be determined because either the highly acidic or highly basic pH of ODF cause irritation and discomfort during administration. The surface pH of all the ODF formulas (F1 to F6) was in the range of 6.95–7.45. The results were tabulated in Figure 7. ODF of atenolol produced in this study exhibited neutral pH, therefore these ODFs are safe and acceptable to be used in the oral cavity without any problem concerning irritation.



**Figure 7.** Surface pH of atenolol oral dissolving films.

### 3.10. Particle Shape and Morphology


The particle shape and morphology of the ODFs were analyzed using a scanning electron microscope. Microscopic images of ODF are shown in Figure 8. Atenolol ODF formulated from HPMC E5 as film former (F1 and F2) showed gritty texture due to the deposition of drug crystals on the film surface. Small pores were also observed in the ODF structure. However, F3 and F4 (formulated from CMC-Na as a film former) exposed lamellar particles with small pores and rough surfaces. Meanwhile, F5 and F6 (formulated from Na-alginate as a film former) produced rough particles with wider pores.



**Figure 8.** Scanning electron microscope image of atenolol ODF in (a) 1000 $\times$  magnification and (b) 5000 $\times$  magnification.

### 3.11. FT-IR Spectrum Analysis

The results of FT-IR spectrum analysis of atenolol, polymer as film former (HPMC E5, CMC-Na, and Na-alginate) and ODF are presented in Figure 9.




**Figure 9.** FT-IR spectrum of (a) Atenolol; (b) HPMC E5; (c) CMC-Na; (d) Na-alginate; (e) ODF produced from HPMC E5 as film former; (f) ODF produced from CMC-Na as film former; and (g) ODF produced from Na-alginate as film former.

The FT-IR spectrum of each ODF revealed an interaction between atenolol and film former. This interaction was observed from the disappearance of atenolol specific band, broadening of -OH stretching of atenolol, and the shifting of carbonyl groups absorption band of atenolol to the lower wavelength number. The interaction between atenolol and film former was predicted as hydrogen bonding.

### 3.12. Molecular Docking Analysis

The free binding energy ( $\Delta G$ ) in silico of atenolol-Na-alginate, and atenolol-CMC Na, were  $-2.22$  and  $-4.80$  kcal/mol, respectively. The  $\Delta G$  in silico for atenolol-HPMC were  $-3.31$  for HPMC I and  $-4.73$  kcal/mol for HPMC II. The interaction of atenolol-Na alginate in silico showed the presence of hydrogen and hydrophobic bonds, as shown in Figure 10a. The hydrogen bonds are located between the H21 atom of atenolol and the O6 atom of the Na-alginate, the O1 atom of atenolol is bonded to H6 atom of Na-alginate, O2 atom of atenolol with two H atoms of Na-alginate (H6 and H8), with binding distances of 2.32, 2.20, 2.13 and 2.42 Å, respectively. The interaction of atenolol-CMC-Na in silico showed hydrogen bonds, as shown in Figure 10b. The hydrogen bonds were between H14 atom of atenolol and O12 of CMC-Na, H15 of atenolol and O4 of CMC-Na, H21 of atenolol and O8 of CMC-Na, and H22 of atenolol and O20 and O5 of CMC-Na with binding distances of 2.02, 2.20, 2.01, 2.55 and 2.17 Å, respectively. The interaction of atenolol-HPMC showed hydrogen bonds, as shown in Figure 10c. The

HPMC had two values of  $\Delta G$  in silico based on the 2D chemical structure depiction of HPMC (Pubchem®Hydroxypropylmethylcellulose compound) resulting in two different molecular structure. The molecular structure of the first HPMC has the IUPAC name of 2R,3R,4S,5R,6R)-2,3,4-trimethoxy-6-(methoxymethyl)-5-[(2S,3R,4S,5R,6R)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxyoxane which is named HPMC I, and the second HPMC has the IUPAC name of 1-[[[(2R,3R,4S,5R,6S)-3,4,5-tris(2-hydroxypropoxy)-6-[(2R,3R,4S,5R,6R)-4,5,6-tris(2-hydroxypropoxy)-2-(2-hydroxypropoxymethyl)oxan-3-yl]oxyoxan-2-yl]methoxy]propan-2-ol which is named HPMC II. Therefore, in this study, docking was carried out on both structures. The interaction of atenolol-HPMC I showed hydrogen bonds between H14 and H5 atoms of atenolol with O8 atom of HPMC I, H21 and H22 atoms of atenolol with O6 atom of HPMC I. The two H atoms were interacted with one O atom with binding distances of 1.86, 2.04, 2.20 and 2.22 Å, respectively. Similar results were found in the interaction of atenolol-HPMC II that showed hydrogen bonds between H14 and H5 atoms of atenolol with O8 atom of HPMC II, H21 of atenolol and O13 of HPMC II, and H22 of atenolol with O6 atom of HPMC with binding distances of 1.87, 2.05, 1.99 and 2.19 Å, respectively.



**Figure 10.** Molecular docking of (a) atenolol-sodium alginate; (b) atenolol-CMC-Na; and (c) atenolol and HPMC (left: I and right: II) indicates the presence of hydrogen and hydrophobic bonds between atenolol and the film former.

#### 4. Discussion

Atenolol is an antihypertension drug which reduces blood pressure primarily via the reduction of cardiac output through chronotropic and inotropic inhibitory mechanisms [15]. Oral dissolving film (ODF) is promising dosage forms to overcome oral route administration problem in specific individuals, especially in geriatric patient who suffer from hypertension [15]. ODF disintegrates and dissolves quickly upon contact with saliva in the oral cavity, accelerating the drug release. Some portion of the drug may be absorbed in the oral cavity, pharynx, and esophagus as the saliva passes down into the stomach. This process is called pre-gastric absorption. Pre-gastric absorption provides bioavailability improvement and rapid onset of action of the drug, including atenolol that undergoes first pass metabolism [5]. The type and concentration of polymer as a film former are

critical parameters determining physical properties, disintegration time, and drug release. Film former used in ODF formulation must exhibit the flexible film, adequate mechanical properties, good wetting, and spreading ability. The film forming capacity of the polymer is described as the ability of a polymer to form a film that can be easily exfoliated from the casting surface without damage or torn [5]. The hydrophilic polymer is preferable to be used in the formulation of ODF as it exhibits sufficient film-forming and swelling capacity that leads to the rapid disintegration of ODF [12]. In this study ODF of atenolol was developed using three different hydrophilic polymers as film former, including HPMC E5, CMC-Na, and Na-alginate. Various concentration of glycerin was used to compensate film former concentration to maintain physical properties of ODF such as thickness and tensile strength and as a wetting agent.

The prepared films were homogenous, yellowish in color, and flexible. HPMC as a film former produced a smooth film surface, while CMC-Na and Na-alginate exhibited a gritty film texture. HPMC E5 showed better film forming capacity and a smooth and transparent appearance [19]. The gritty texture of ODF, when using CMC-Na and Na-alginate as film former, was predicted due to inconsistency of polymer thickness and bubble entrapment during the casting process [20]. Crystallization of atenolol in the film matrix was also possible to produce gritty texture in ODF with CMC-Na and Na-alginate polymers. Crystallization of the drug possibility occurs because the viscosity of matrix composition was not adequate to prevent drug sedimentation [21].

The thickness of ODF was evaluated with a screw gauge in order to evaluate the film homogeneity and the reproducibility of the preparation method. The thickness uniformity is also directly associated with the dose uniformity. The results exhibited that these polymers (HPMC E5, CMC-Na, and Na-alginate) are suitable for producing a good film thickness uniformity. The film thickness of ODF prepared in this study was in the range of 0.116 mm to 0.233 mm, so that the ODF of atenolol provides suitable film thickness (<0.3 mm) [15]. ODF was cut to size 3 × 2 cm film, then the weight of ODF was evaluated. All prepared formulas exhibited an excellent uniformity of weight with low deviation among manufacturing replications. The increased of film former concentration resulted in the increase of ODF thickness, which is implicated in an increase in the weight of the formulated ODF [22]. Atenolol content in ODF was analyzed using UPLC instrument. The results showed that the drug content is relatively high in all formulas. This phenomenon is related to the thickness homogeneity of ODF, resulting from pouring process in the solvent casting method. Homogeneity of thickness is an essential physical parameter in ODF evaluation as it has substantial implication for the precision of dose distribution of ODF [23]. An increased in the ODF thickness reflects an increase in drug content and variety of mass [22]. ODF, when using CMC-Na as a film former (F3 and F4), exhibited wider variation of film thickness compared to the other formulas. This condition probably occurred due to the more viscous casting mass of ODF when using CMC-Na as a film former. More viscous solutions are disadvantages because of de-aeration problem and non-homogeneity distribution on a casting plate [21].

ODF of atenolol prepared using HPMC E5 and CMC-Na as film former presents good folding endurance (>300 times) [13]. These results indicated that those ODFs are tough and flexible. Nevertheless, sodium alginate produced ODF with poor folding endurance. This characteristic in line with the previous study, which revealed that Na-alginate exhibited brittle film properties, possibly due to the stiffness gel structure. The increase of sodium alginate concentration in ODF formulation produces less flexible film properties [24]. From the results of mechanical properties, HPMC exhibited superior film forming ability, physical appearance, and flexibility.

The swelling property is an essential parameter in ODF formulation. The swelling index is a parameter to describe ODF swelling property when in contact with an aqueous medium [25]. Hydrophilic film former in ODF needs to take up water, swell, and disintegrate rapidly in order to release the drug. The swelling index indicates the ability of polymer to absorb water. The extent of swelling in polymers is a resultant of the free

energy of mixing and the elastic refractile force, which opposes the deformation [26]. The high values of swelling index indicate that the polymer can be easily penetrated by water molecule [27]. ODF prepared using CMC-Na as a film former showed the highest value of swelling index compared to the others. This phenomenon occurred because CMC-Na has high swelling properties. Hence HPMC and sodium alginate have moderate swelling properties [28]. The swelling rate of CMC-Na hydrogel was very high in the initial period until reaching the equilibrium of swelling. The pH of ODF was around neutral pH (pH = 7), hence CMC-Na exhibited optimum swelling in this situation. The result of this evaluation also revealed that the increased concentration of each film former did not reveal a significant difference in the swelling index of ODF.

A disintegration time test in artificial saliva was carried out to predict the ability of ODF to disintegrate into fragments in the oral cavity. The disintegration time of ODF prepared in this study ranged from 13.26 to 50.46 s. All of the film formers produced a suitable disintegration time of ODF, which was less than 60 s [20]. The result also revealed that increasing the concentration of the film former also increased the time needed for ODF to disintegrate. The concentration of the film former influenced the viscosity of the film matrix. The viscosity of the film matrix increased with the increase in the concentration of film former, therefore lengthen the disintegration time of ODF [29]. Na-alginate produced a significantly faster disintegration time of ODF (F5 and F6) compared to the other four formulas ( $p < 0.05$ ). These results revealed that film thickness and swelling index significantly influenced the ODF disintegration time. The ODF of atenolol prepared using Na-alginate as a film former afforded the lowest film thickness and moderate swelling property. Therefore, these characteristics leads to a faster disintegration time of F5 and F6. ODF with CMC-Na as a film former showed the highest swelling index but exhibited the slowest disintegration time compare to the other film formers. This is due to the great swelling behavior and entrapment of water molecules in the polymer matrix resulting in gel formation, making the disintegration time slower [30].

ODFs of atenolol is required to release the drug in specific amount of the predetermined time limit. The amount of drug dissolved from ODF prepared using HPMC E5 as a film former, was significantly different from CMC-Na and Na-alginate ( $p < 0.05$ ). In-vitro drug dissolution study revealed that HPMC E5 as a film former produced the highest percentage of drug dissolved in 30 min. HPMC exhibited a swelling-erosion mechanism of drug release within a film matrix. The previous study also revealed that HPMC induced rapid swelling and erosion. This mechanism proposes a rapid dissolution of the drug from the HPMC film matrix, despite the shortest disintegration time shown by Na-alginate as film former [31]. Na-alginate showed more retardation of drug release due to excessive swelling index than HPMC as film former [30]. Furthermore, as the concentration of film former increased, the drug release decreased due to the thickening of drug-film layer around the ODF. The increased of film former concentration also increased the wetting and dissolving time of ODF matrix [13].

The surface pH of ODF was evaluated to predict its possible effect on the mucous membrane of the mouth during the use of this dosage form. In the fact, acidic and basic oral formulation can cause an inflammatory reaction of the oral mucosa. Therefore, ODF formulation with neutral pH was intended in this study. The pH measurement results on the surface of the six ODFs in this study exhibited neutral pH, ranged from 6.94 to 7.4. These results indicated that ODFs would not irritate the oral mucosa and are acceptable to the patients.

The particle shape and morphology of the ODFs were observed by a scanning electron microscope. Microscopic images of ODF revealed that formulas with HPMC E5 (F1 and F2) as a film former were gritty in texture, contained small pores, and the drug crystal was deposited in small particles on the surface of ODFs. The small pores in these ODFs indicate that water molecules can penetrate the film's structure and shorten the disintegration time [32]. These findings supported the phenomenon that HPMC-based ODFs (F1 and F2) in this study are characterized by fast hydration, rapid disintegration, and quick dissolving

of the drugs. However, ODF formulas with CMC-Na (F3 and F4) as a film former exposed high number of small pores and rough surfaces. The drug should dissolve in the film, but some portions of the drug was crystallized and adhered to the surface of ODFs. The drug crystal on the surface of ODF prepared using CMC Na was significantly larger than the ODFs prepared using the other formulas. This phenomenon was predicted as the excessive recrystallization of the drug in the film surface, indicating the matrix system was not strong enough to prevent drug sedimentation and crystallization [32]. Meanwhile, sodium alginate as a film former produced a rough, porous structure and widely open pores. Thus, the disintegration time of sodium alginate based ODFs (F5 and F6) was significantly faster than the other film formers. The observed drugs were homogeneously distributed in the matrix cell wall of these formulas. In a further study, the drug deposition and distribution in the film matrix must be optimized to ensure the uniformity content of the drug. The inclusion complex of the drug using cyclodextrin or particle size reduction approach can be utilized to enhance content uniformity in each film [33].

The FT-IR spectroscopy study was conducted to analyze functional group and its vibration characteristic in ODF formulations. This analysis can predict the possible interaction between the drug and film former in ODFs. FT-IR spectrum of atenolol displayed a specific absorption band at  $3400\text{ cm}^{-1}$  and  $3100\text{ cm}^{-1}$  corresponding to the N-H group. The specific absorption band of atenolol at  $1895\text{ cm}^{-1}$  represented the C=O bond. Hence absorption bands at  $1660.41\text{ cm}^{-1}$  revealed the existence of C=O-N group. From the spectrum of ODFs, a slightly difference absorption band of -NH group of atenolol was observed. The absence or shifting of the carbonyl groups absorption band of atenolol was observed in ODFs spectrum. The broadening absorption band of -OH group in film former was also reflected. These results indicated the hydrogen bonding interaction between atenolol and film former [33].

Molecular docking analysis was also conducted in this study to predict and explain the results of the experimental study [34]. The affinity of the drug and excipient in silico was analyzed by the  $\Delta G$  in silico. The higher affinity of the drug-excipient, the lower the  $\Delta G$  in silico [35]. The  $\Delta G$  in silico of atenolol-HPMC was the highest compared to atenolol-Na-alginate and atenolol-CMC Na. The results supported the experimental study.

The 3-D visualization of atenolol-Na-alginate in silico showed hydrogen and hydrophobic bonds. These results supported FTIR spectra of atenolol-sodium alginate, indicating hydrogen bonds between -NH (amine group) of atenolol and -OH group of Na-alginate. The 3-D visualization of atenolol-CMC Na in silico showed hydrogen bonds. These results supported FTIR spectra of atenolol-CMC Na that indicated hydrogen bonding, involving-N-H (amine) group of atenolol and -OH group of carboxylic acids in CMC-Na. The other interaction was also predicted to occur between the -N-H (amine) group of atenolol and the C=O (carbonyl) group of CMC-Na. The 3-D visualization of atenolol-HPMC in silico showed hydrogen bonds. These results supported FTIR spectra of atenolol-HPMC that indicated hydrogen bond interaction involving the amino and carbonyl groups of atenolol with the hydrogen group of HPMC E5. The molecular docking results supported the FT-IR spectrum analysis and revealed the hydrogen bonding between atenolol and each film former.

## 5. Conclusions

In this study, atenolol was prepared as oral dissolving films by a convenient solvent casting method. Six formulas were developed using three different film formers (HPMC E5, CMC-Na and Na-alginate) and two different concentrations of each film former. FT-IR spectrum and molecular docking analysis revealed the presence of hydrogen bonding interaction between atenolol and film former. ODF formulas developed in this study exhibited rapid disintegration time and drug release due to the porous structure confirmed by SEM analysis. Satisfactory results were obtained from several physical parameters including film thickness, folding endurance, swelling index, and disintegration time. However, HPMC E5 showed better film forming ability, physical properties, drug content

homogeneity, and drug release profile compared to the other film formers. Formula 1 prepared using 4% (*w/v*) HPMC E5 is the most preferred formula to be developed in the further study.

**Author Contributions:** Conceptualization, K.C.R. and N.P.; methodology, A.N.W. and E.W.F.; software, A.T.P. and N.L.D.A.; validation, N.L.D.A., K.C.R. and C.A.; investigation, F.I., F.A. and C.Y.; writing—original draft preparation, K.C.R., R.N. and A.T.P.; writing—review and editing, A.R.P., C.A.; supervision, C.A. All authors have read and agreed to the published version of the manuscript.

**Funding:** This publication was partially funded by the Institute for Research and Community Services at the University of Surabaya. No external funding was received in this study.

**Institutional Review Board Statement:** Not applicable.

**Informed Consent Statement:** Not applicable.

**Data Availability Statement:** Not applicable.

**Acknowledgments:** The authors express their gratitude to PT. Kalbe Farma, Tbk for supporting materials (atenolol and Poloxamer 188) used in this study.

**Conflicts of Interest:** The authors declare no conflict of interest.

## References

1. Hoffmann, E.M.; Breitenbach, A.; Breikreutz, J. Advances in orodispersible films for drug delivery. *Expert Opin. Drug Deliv.* **2011**, *8*, 299–316. [CrossRef]
2. Kumar, C.; Verma, S.; Singh, B.; Haque, A.; Satija, S.; Vyas, M. A review on conventional and modern techniques to develop Orodispersible films. *Asian J. Pharm.* **2018**, *12*, S433–S438.
3. Dixit, R.P.; Puthli, S.P. Oral strip technology: Overview and future potential. *J. Control. Release* **2009**, *139*, 94–107. [CrossRef] [PubMed]
4. Low, A.Q.J.; Parmentier, J.; Khong, Y.M.; Chai, C.C.E.; Tun, T.Y.; Berania, J.E.; Liu, X.; Gokhale, R.; Chan, S.Y. Effect of type and ratio of solubilising polymer on characteristics of hot-melt extruded orodispersible films. *Int. J. Pharm.* **2013**, *455*, 138–147. [CrossRef] [PubMed]
5. Nalluri, B.N.; Sravani, B.; Anusha, V.S.; Sribramhini, R.; Maheswari, K.M. Development and Evaluation of Mouth Dissolving Films of Sumatriptan Succinate for Better Therapeutic Efficacy. *J. Appl. Pharm. Sci.* **2013**, *3*, 161–166. [CrossRef]
6. Bala, R.; Sharma, S. Formulation optimization and evaluation of fast dissolving film of aprepitant by using design of experiment. *Bull. Fac. Pharm. Cairo Univ.* **2018**, *56*, 159–168. [CrossRef]
7. Elmeshad, A.N.; El Hagrasy, A.S. Characterization and optimization of orodispersible mosapride film formulations. *AAPS PharmSciTech* **2011**, *12*, 1384–1392. [CrossRef]
8. Abdelbary, A.; Bendas, E.R.; Ramadan, A.A.; Mostafa, D.A. Pharmaceutical and Pharmacokinetic Evaluation of a Novel Fast Dissolving Film Formulation of Flupentixol Dihydrochloride. *Ageing Int.* **2014**, *15*, 1603–1610. [CrossRef]
9. Raza, S.N.; Kar, A.H.; Wani, T.U.; Khan, N.A. Formulation and evaluation of mouth dissolving films of losartan potassium using 32 Factorial design. *Int. J. Pharm. Sci. Res.* **2019**, *10*, 1402–1411. [CrossRef]
10. Satyanarayana, D.A.; Keshavarao, K.P. Fast disintegrating films containing anastrozole as a dosage form for dysphagia patients. *Arch. Pharm. Res.* **2012**, *35*, 2171–2182. [CrossRef]
11. Koteswari, P.; Sravanthi, G.P.; Mounika, M.; Mohammed Rafi, S.; Nirosha, K. Formulation development and evaluation of zolmitriptan oral soluble films using 2 2 factorial designs. *Int. J. Pharm. Investig.* **2016**, *6*, 201. [CrossRef] [PubMed]
12. Benavides, S.; Villalobos-Carvajal, R.; Reyes, J.E. Physical, mechanical and antibacterial properties of alginate film: Effect of the crosslinking degree and oregano essential oil concentration. *J. Food Eng.* **2012**, *110*, 232–239. [CrossRef]
13. Kathpalia, H.; Patil, A. Formulation and evaluation of orally disintegrating films of levocetirizine dihydrochloride. *Indian J. Pharm. Sci.* **2017**, *79*, 204–211. [CrossRef]
14. Yir-Erong, B.; Bayor, M.T.; Ayensu, I.; Gbedema, S.Y.; Boateng, J.S. Oral thin films as a remedy for noncompliance in pediatric and geriatric patients. *Ther. Deliv.* **2019**, *10*, 443–464. [CrossRef] [PubMed]
15. Hussain, A.; Latif, S.; Abbas, N.; Irfan, M.; Arshad, M.S.; Bukhari, N.I. Hydroxypropyl cellulose-based orally disintegrating films of promethazine HCL for the treatment of motion sickness. *Trop. J. Pharm. Res.* **2018**, *17*, 991–996. [CrossRef]
16. Irfan, M.; Rabel, S.; Bukhtar, Q.; Qadir, M.I.; Jabeen, F.; Khan, A. Orally disintegrating films: A modern expansion in drug delivery system. *Saudi Pharm. J.* **2016**, *24*, 537–546. [CrossRef]
17. Atenolol Injection USP Monograph. Available online: <https://online.uspnf.com/> (accessed on 23 December 2020).
18. Shen, B.; De Shen, C.Y.; Yuan, X.D.; Bai, J.X.; Lv, Q.Y.; Xu, H.; Dai, L.; Yu, C.; Han, J.; Yuan, H.-L. Development and characterization of an orodispersible film containing drug nanoparticles. *Eur. J. Pharm. Biopharm.* **2013**, *85*, 1348–1356. [CrossRef]



19. Galgatte, U.C.; Khanchandani, S.S.; Jadhav, Y.G.; Chaudhari, P.D. Investigation of different polymers, plasticizers and superdisintegrating agents alone and in combination for use in the formulation of fast dissolving oral films. *Int. J. PharmTech Res.* **2013**, *5*, 1465–1472.
20. Ouda, G.I.; Dahmash, E.Z.; Alyami, H.; Iyire, A. A Novel Technique to Improve Drug Loading Capacity of Fast/Extended Release Orally Dissolving Films with Potential for Paediatric and Geriatric Drug Delivery. *AAPS PharmSciTech* **2020**, *21*, 1–14. [[CrossRef](#)]
21. Centkowska, K.; Lawrecka, E.; Sznitowska, M. Technology of orodispersible polymer films with micronized loratadine—Influence of different drug loadings on film properties. *Pharmaceutics* **2020**, *12*, 250. [[CrossRef](#)]
22. Maheswari, K.M.; Devineni, P.K.; Deekonda, S.; Shaik, S.; Uppala, N.P.; Nalluri, B.N. Development and Evaluation of Mouth Dissolving Films of Amlodipine Besylate for Enhanced Therapeutic Efficacy. *J. Pharm.* **2014**, *2014*, 520949. [[CrossRef](#)] [[PubMed](#)]
23. Al-Ghabban, F.M.; Al-Ani, I.H.; Hassan, S.F.; Salan, N. Formulation of Prifinium Bromide and Prifinium Bromide-Diclofenac Sodium combination as orodispersible tablets. *Int. J. Pharm. Pharm. Sci.* **2013**, *5*, 652–659.
24. Kaczmarek, B. Improving sodium alginate films properties by phenolic acid addition. *Materials* **2020**, *13*, 2895. [[CrossRef](#)]
25. Asthana, G.S.; Sharma, S.; Asthana, A. Formulation and evaluation of alginate-based mucoadhesive buccal patch for delivery of antimigraine drug. *Asian J. Pharm. Clin. Res.* **2018**, *11*, 185–191. [[CrossRef](#)]
26. Ayorinde, J.O.; Odeniyi, M.A.; Balogun-Agbaje, O. Formulation and Evaluation of Oral Dissolving Films of Amlodipine Besylate Using Blends of Starches with Hydroxypropyl Methyl Cellulose. *Polim. Med.* **2016**, *46*, 45–51. [[CrossRef](#)]
27. Ayorinde, J.O.; Effiong, D.E.; Odeniyi, M.A. Design and evaluation of oral dissolving films of chlorpheniramine from native and modified enterolobium cyclocarpum gum. *Afr. J. Biomed. Res.* **2018**, *21*, 175–182.
28. Najafi, R.B.; Rezaei, Z.; Najm, O. Formulation and evaluation of phenytoin sodium buccoadhesive polymeric film for oral wounds. *Iran. J. Pharm. Sci.* **2011**, *7*, 69–77.
29. Bonsu, M.A.; Ofori-Kwakye, K.; Kipo, S.L.; El Boakye-Gyasi, M.; Fosu, M.-A. Development of Oral Dissolvable Films of Diclofenac Sodium for Osteoarthritis Using Albizia and Khaya Gums as Hydrophilic Film Formers. *J. Drug Deliv.* **2016**, *2016*, 6459280. [[CrossRef](#)] [[PubMed](#)]
30. Dawaba, A.M.; Dawaba, H.M.; Abu El-Enin, A.S.M.; Khalifa, M.K.A. Fabrication of bioadhesive ocusert with different polymers: Once a day dose. *Int. J. Appl. Pharm.* **2018**, *10*, 309–317. [[CrossRef](#)]
31. Adrover, A.; Varani, G.; Paolicelli, P.; Petralito, S.; Di Muzio, L.; Casadei, M.A.; Tho, I. Experimental and modeling study of drug release from HPMC-based erodible oral thin films. *Pharmaceutics* **2018**, *10*, 222. [[CrossRef](#)]
32. Shi, L.L.; Xu, W.J.; Cao, Q.R.; Yang, M.; Cui, J.H. Preparation, characterization and in vitro evaluation of a polyvinyl alcohol/sodium alginate based orodispersible film containing sildenafil citrate. *Pharmazie* **2014**, *69*, 327–334. [[CrossRef](#)] [[PubMed](#)]
33. Reddy, K.A.; Karpagam, S. Cellulose Orodispersible Films of Donepezil: Film Characterization and Drug Release. *Pharm. Chem. J.* **2017**, *51*, 707–715. [[CrossRef](#)]
34. Akyüz, L.; Duman, F.; Kaya, M. Püskürtmeli Kurutma Tekniği Kullanarak Flurbiprofenin Kitosan ile Enkapsülasyonu ve İn Vitro İlaç Salınımı ve Moleküler Modelleme Çalışmaları. *Turk. J. Pharm. Sci.* **2017**, *14*, 34–39. [[CrossRef](#)] [[PubMed](#)]
35. Firdaus, M.A.; Maarof, H. Multiple docking of  $\alpha$ -,  $\beta$ -, and  $\gamma$ -cyclodextrin with vinpocetine chiral complexes. *EProceedings Chem.* **2017**, *2*, 12–17.



*pharmaceuticals*




Ads by Google

Stop seeing this ad Why this ad?

# Pharmaceutics

### COUNTRY

Switzerland

 Universities and research institutions in Switzerland

### SUBJECT AREA AND CATEGORY

Pharmacology, Toxicology and  
Pharmaceutics  
Pharmaceutical Science

### PUBLISHER

MDPI Multidisciplinary Digital Publishing Institute

### H-INDEX

# 50

### PUBLICATION TYPE

Journals

### ISSN

19994923

### COVERAGE

2010-2020

### INFORMATION

[Homepage](#)  
[How to publish in this journal](#)  
[yvonne.perrie@strath.ac.uk](mailto:yvonne.perrie@strath.ac.uk)

Ads by Google

Stop seeing this ad Why this ad?

### SCOPE

Pharmaceutics (ISSN 1999-4923) is an open access journal which provides an advanced forum for the science and technology of pharmaceutics and biopharmaceutics. It publishes reviews, regular research papers, communications, opinions, commentaries, and short notes. Covered topics include pharmaceutical formulation, process development, drug delivery, pharmacokinetics, biopharmaceutics, pharmacogenetics, and interdisciplinary research involving, but not limited to, engineering, biomedical sciences, and cell biology. Our aim is to encourage scientists to publish their experimental results and theoretical assumptions in as much detail as possible. There is no restriction on the length of the papers. The full experimental details must be provided so that the results can be reproduced. In addition, this journal presents the following unique features: Manuscripts regarding research proposals and research ideas will be particularly welcomed. Computed data or files regarding the full details of the experimental procedures can be deposited as supplementary material if it is not possible to publish them in the Material and Methods section, as usual. We also accept manuscripts addressed to a broader audience, regarding research projects financed by public funds.

 Join the conversation about this journal

Open Access Journal  
NN Journals Are Double-Blind Peer-Reviewed Open Access Journals Available Online nnpub.org

## Register For Free


The summit will convene 100 speakers & 2,000 participants virtually 4 days: Dec 6-10.

World Ocean Summit

### FIND SIMILAR JOURNALS ?

options :

<p>1 <b>Drug Delivery and Translational Research</b> USA</p> <p><b>93%</b> similarity</p>	<p>2 <b>Current Drug Delivery</b> ARE</p> <p><b>92%</b> similarity</p>	<p>3 <b>Journal of Drug Delivery Science and Technology</b> FRA</p> <p><b>89%</b> similarity</p>	<p>4 <b>Therapeutic Delivery</b> GBR</p> <p><b>89%</b> similarity</p>	<p>5 <b>Expert Opinion on Drug Delivery</b> GBR</p> <p><b>88%</b> similarity</p>
---	--	--	---	--



**Pharmaceutics**

Q1 Pharmaceutical Science  
best quartile

SJR 2020 1.05

powered by scimagojr.com

Show this widget in your own website

Just copy the code below and paste within your html code:

`<a href="https://www.scimagojr.com">`

### SCImago Graphica

Explore, visually communicate and make sense of data with our new free tool.

Get it



Open Access Journal  
NN Journals Are Double-Blind Peer-Reviewed Open Access Journals Available Online nnpub.org

Metrics based on Scopus® data as of April 2021

N **nita** 1 year ago  
hello,  
how much percent plagiarism is accepted?  
  
reply



**Melanie Ortiz** 1 year ago

SCImago Team

Dear Nita,  
thank you for contacting us.  
We are sorry to tell you that SCImago Journal & Country Rank is not a journal. SJR is a portal with scientometric indicators of journals indexed in Elsevier/Scopus.  
Unfortunately, we cannot help you with your request, we suggest you visit the journal's homepage or contact the journal's editorial staff , so they could inform you more deeply.  
Best Regards, SCImago Team

F **forouzan** 2 years ago  
Im pharmacy student  
  
reply



**Melanie Ortiz** 2 years ago

SCImago Team

Dear user, thanks for your participation! Best Regards, SCImago Team

#### Leave a comment

Name

Email

(will not be published)

I'm not a robot RECAPTCHA  
Privacy - Terms

Submit

The users of Scimago Journal & Country Rank have the possibility to dialogue through comments linked to a specific journal. The purpose is to have a forum in which general doubts about the processes of publication in the journal, experiences and other issues derived from the publication of papers are resolved. For topics on particular articles, maintain the dialogue through the usual channels with your editor.

Developed by:



Powered by:



Follow us on @ScimagoJR

Scimago Lab, Copyright 2007-2020. Data Source: Scopus®





# Source details

## Pharmaceutics

Open Access ⓘ

Scopus coverage years: from 2010 to Present

Publisher: Multidisciplinary Digital Publishing Institute (MDPI)

ISSN: 1999-4923

Subject area: Pharmacology, Toxicology and Pharmaceutics: Pharmaceutical Science

Source type: Journal

CiteScore 2020

4.7 ⓘ

SJR 2020

1.054 ⓘ

SNIP 2020

1.543 ⓘ

[View all documents >](#)

[Set document alert](#)

[Save to source list](#)

[CiteScore](#) [CiteScore rank & trend](#) [Scopus content coverage](#)

### i Improved CiteScore methodology

CiteScore 2020 counts the citations received in 2017-2020 to articles, reviews, conference papers, book chapters and data papers published in 2017-2020, and divides this by the number of publications published in 2017-2020. [Learn more >](#)

CiteScore 2020 ▾

$$4.7 = \frac{10,500 \text{ Citations } 2017 - 2020}{2,238 \text{ Documents } 2017 - 2020}$$

Calculated on 05 May, 2021

CiteScoreTracker 2021 ⓘ

$$5.7 = \frac{21,024 \text{ Citations to date}}{3,689 \text{ Documents to date}}$$

Last updated on 05 October, 2021 • Updated monthly

## CiteScore rank 2020 ⓘ

Category	Rank	Percentile
Pharmacology, Toxicology and Pharmaceutics	#52/166	68th
Pharmaceutical Science		

[View CiteScore methodology >](#) [CiteScore FAQ >](#) [Add CiteScore to your site ↗](#)

## About Scopus

[What is Scopus](#)  
[Content coverage](#)  
[Scopus blog](#)  
[Scopus API](#)  
[Privacy matters](#)

## Language

[日本語に切り替える](#)  
[切换到简体中文](#)  
[切换到繁體中文](#)  
[Русский язык](#)

## Customer Service

[Help](#)  
[Contact us](#)

**ELSEVIER**

[Terms and conditions](#) ↗ [Privacy policy](#) ↗

Copyright © Elsevier B.V. ↗. All rights reserved. Scopus® is a registered trademark of Elsevier B.V.

We use cookies to help provide and enhance our service and tailor content. By continuing, you agree to the use of cookies.

 RELX



Search for Articles:

Title / Keyword

MDPI / Keyword

Pharmaceutics

All Article Types

Search

Advanced

Journals / Pharmaceutics



pharmaceutics

Submit to Pharmaceutics

Review for Pharmaceutics



Share

## Journal Menu

- Pharmaceutics Home
- ▲ Aims & Scope
- ▲ Editorial Board
- ▲ Reviewer Board
- ▲ Topical Advisory Panel
- ▲ Instructions for Authors
- ▲ Special Issues
- ▲ Sections & Collections
- ▲ Article Processing Charge
- ▲ Indexing & Archiving
- ▲ Most Cited & Viewed
- ▲ Journal Statistics
- ▲ Journal History
- ▲ Journal Awards
- ▲ Society Collaborations

## Pharmaceutics

Pharmaceutics is a peer-reviewed, open access journal on the science and technology of pharmaceutics and biopharmaceutics, and is published monthly online by MDPI. The Spanish Society of Pharmaceutics and Pharmaceutical Technology (SEFIG), Pharmaceutical Solid State Research Cluster (PSSRC), Academy of Pharmaceutical Sciences (APS) and Korean Society of Pharmaceutical Sciences and Technology (KSPST) are affiliated with Pharmaceutics and their members receive a discount on the article processing charges.

- **Open Access** — free for readers, with article processing charges (APC) paid by authors or their institutions.
- **High Visibility:** indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CABIplus / SciFinder, and many other databases.
- **Journal Rank:** [JCR](#) - Q1 (Pharmacology & Pharmacy) / [CiteScore](#) - Q2 (Pharmaceutical Science)
- **Rapid Publication:** manuscripts are peer-reviewed and a first decision provided to authors approximately 13.5 days after submission; acceptance to publication is undertaken in 3.7 days (median values for papers published in this journal in the first half of 2021).
- **Recognition of Reviewers:** reviewers who provide timely, thorough peer-review reports receive vouchers entitling them to a discount on the APC of their next publication in any MDPI journal, in appreciation of the work done.
- **Companion Journal:** *Future Pharmacology*

Impact Factor: 6.321 (2020) ; 5-Year Impact Factor: 6.734 (2020)

Imprint Information Journal Flyer Open Access ISSN: 1599-4923

IMPACT  
FACTOR  
6.321Covered in  
PubMed

## E-Mail Alert

Add your e-mail address to receive forthcoming issues of this journal:

Subscribe

## News

23 September 2021

2020 MDPI Top Reviewer Award—Winners Announced



22 September 2021

MDPI Joins SDG Publishers Compact

3 August 2021

Announcement on Japanese Consumption Tax (JCT)

---

## Editorial Board

- [Editorial Board](#)
- [Nanomedicine and Nanotechnology Section](#)
- [Pharmaceutical Technology, Manufacturing and Devices Section](#)
- [Physical Pharmacy and Formulation Section](#)
- [Biopharmaceutics Section](#)
- [Drug Delivery and Controlled Release Section](#)
- [Pharmacokinetics and Pharmacodynamics Section](#)
- [Gene and Cell Therapy Section](#)
- [Drug Targeting and Design Section](#)
- [Biologics and Biosimilars Section](#)
- [Clinical Pharmaceutics Section](#)

### Editors (8)

**Prof. Dr. Yvonne Perrie** [Website](#)

*Editor-in-Chief*

Strathclyde Institute of Pharmacy and Biomedical Sciences, University of Strathclyde, Glasgow G4 0RE, UK

**Interests:** particulate systems and formulations for drug delivery, vaccine adjuvancy and diagnostics

[Special Issues and Collections in MDPI Journals](#)



**Prof. Dr. Beom Soo Shim** [Website](#) [SciProfiles](#)

*Section Editor-in-Chief*

School of Pharmacy, Sungkyunkwan University, Suwon, Gyeonggi-do 16419, Korea

**Interests:** pharmacokinetics; translational PKPD modeling; PBPK modeling; in vitro–in vivo correlation; pharmaceutical analysis; 3D printing

[Special Issues and Collections in MDPI Journals](#)



**Prof. Dr. Donatella Paolino** [Website](#) [SciProfiles](#)

*Section Editor-in-Chief*

Department of Experimental and Clinical Medicine, University Magna Graecia of Catanzaro, 88100 Catanzaro, Italy

**Interests:** nanomedicine; drug delivery; gene therapy; pharmaceutics; pharmaceutical education; topical delivery

[Special Issues and Collections in MDPI Journals](#)



**Prof. Dr. Jaehwi Lee** [SciProfiles](#)

*Section Editor-in-Chief*

College of Pharmacy, Chung-Ang University, Seoul 06974, Korea

**Interests:** solubilization; bioavailability; particle technologies; lipid-based drug delivery; formulation design

[Special Issues and Collections in MDPI Journals](#)



**Prof. Dr. Patrick J. Sinko** [Website](#) [SciProfiles](#)

*Section Editor-in-Chief*

Ernest Mario School of Pharmacy, Rutgers, The State University of New Jersey, William Levine Hall, Room 225C, 160

Frellinghuysen Road, Piscataway, NJ 08854-6020, USA

**Interests:** drug delivery; nanotechnology; biopharmaceutics; pharmacokinetics; absorption; permeability; AIDS; cancer

[Special Issues and Collections in MDPI Journals](#)



**Prof. Dr. Thierry Vandamme** [Website](#) [SciProfiles](#)

*Section Editor-in-Chief*

Laboratory for the Conception and Application of Bioactive Molecules, Faculty of Pharmacy, University of Strasbourg,

67400 Illkirch-Graffenstaden, France

**Interests:** microencapsulation; nanoemulsions; biopharmacy; formulation; pharmaceutical engineering

[Special Issues and Collections in MDPI Journals](#)



**Prof. Dr. Ruggero Bettini** [Website](#) [SciProfiles](#)

*Associate Editor*

Food and Drug Department, University of Parma, Parco Area delle Scienze 27/A, 43124 Parma, Italy

**Interests:** supercritical fluids; solid state chemistry; particle and crystal engineering; oral delivery; polymeric scaffolds; powders for transmucosal and pulmonary drug delivery; industrial pharmacy



**Prof. Dr. Afzal R. Mohammed** [Website](#)

*Associate Editor*

Aston Pharmacy School, School of Life and Health Sciences, Aston University, Aston Triangle, Birmingham B4 7ET, UK

**Interests:** freeze drying; fast disintegrating tablets; reformulation of medicines; microarray

[Special Issues and Collections in MDPI Journals](#)



### Editorial Board Members (397)

## Pharmaceutics, Volume 13, Issue 10 (October 2021) – 212 articles

- Issues are regarded as officially published after their release is announced to the [table of contents alert mailing list](#).
- You may [sign up for e-mail alerts](#) to receive table of contents of newly released issues.
- PDF is the official format for papers published in both, html and pdf forms. To view the papers in pdf format, click on the "PDF Full-text" link, and use the free [Adobe Reader](#) to open them.

Order results

Publication Date

Result details

Normal

Show export options

Open Access Article



### Non-Clinical In Vitro Evaluation of Antibiotic Resistance Gene-Free Plasmids Encoding Human or Murine IL-12 Intended for First-in-Human Clinical Study

by [Spela Kos](#), [Masa Bosnjak](#), [Tanja Jesenko](#), [Bostjan Markic](#), [Urška Kamensek](#), [Katarina Znidar](#), [Urška Matkovic](#), [Andrej Rencelj](#), [Gregor Sersa](#), [Rosana Hudej](#), [Aneja Tuljak](#), [Matjaz Peterka](#) and [Maja Camazar](#)

Pharmaceutics 2021, 13(10), 1739; <https://doi.org/10.3390/pharmaceutics13101739> - 19 Oct 2021

Viewed by 279

**Abstract** Interleukin 12 (IL-12) is a key cytokine that mediates antitumor activity of immune cells. To fulfill its clinical potential, the development is focused on localized delivery systems, such as gene electrotransfer, which can provide localized delivery of IL-12 to the tumor microenvironment. [Gene \[...\]](#) [Read more](#).

(This article belongs to the Special Issue *Advances in Physics Methods for Drug Delivery*)

[► Show Figures](#)

Open Access Article



### Lessons Learned in Protein Precipitation Using a Membrane Emulsification Technique to Produce Reversible and Uniform Microbeads

by [Sang-Koo Park](#), [Ga Yeon Noh](#), [Hyun Woo Yu](#), [Eun Chae Lee](#), [Junoh Jeong](#), [Young-Min Park](#), [Hyo-Kyung Han](#), [Seong Hoon Jeong](#) and [Nam Ah Kim](#)

Pharmaceutics 2021, 13(10), 1738; <https://doi.org/10.3390/pharmaceutics13101738> - 19 Oct 2021

Viewed by 181

**Abstract** The effects of the manufacturing process and the regeneration of Shirasu porous glass (SPG) membranes were investigated on the reproducibility of protein precipitants, termed protein microbeads. Intravenous immunoglobulin (IVIg) was selected as a model protein to produce its microbeads in seven different cases. [\[...\] Read more](#).

(This article belongs to the Special Issue *Application of Supercritical Fluid and Compressed Gas in Pharmaceutical Technology*)

[► Show Figures](#)

Open Access Article



### Anti-Inflammatory Effect of Tacrolimus/Hydroxypropyl- $\beta$ -Cyclodextrin Eye Drops in an Endotoxin-Induced Uveitis Model

by [Xurxo Garcia-Otero](#), [Cristina Mondelo-García](#), [Francisco González](#), [Roman Perez-Fernandez](#), [Leandro Avila](#), [Jose Ramón Antúnez-López](#), [Miguel González-Barcia](#), [Alfredo Adan](#), [Pablo Aguilar](#), [Francisco J. Otero-Espinar](#), [María A. Bermúdez](#) and [Anxo Fernández-Ferreiro](#)

Pharmaceutics 2021, 13(10), 1737; <https://doi.org/10.3390/pharmaceutics13101737> - 19 Oct 2021

Viewed by 235

**Abstract** Background: Uveitis is an infrequent disease which constitutes a major cause of ocular morbidity. Correct management is essential, being corticosteroids its cornerstone. In case of contraindication to corticosteroids or treatment failure, the use of topical tacrolimus (TAC) could be an alternative which has [\[...\] Read more](#).

(This article belongs to the Special Issue *Ophthalmic Drug Delivery Volume II*)

[► Show Figures](#)

Open Access Article



## In Vitro Cellular and Molecular Interplay between Human Foreskin-Derived Mesenchymal Stromal/Stem Cells and the Th17 Cell Pathway

by Mehdi Najar, Makram Merimi, Wissam H. Faour, Catherine A. Lombard, Douaa Moussa Agha, Yassine Ouahdi, Etienne M. Sokal, Laurence Lagneaux and Hassan Fahmi

Pharmaceutics 2021, 13(10), 1736; <https://doi.org/10.3390/pharmaceutics13101736> - 19 Oct 2021

Viewed by 188

**Abstract** Foreskin, considered a biological waste material, has been shown to be a reservoir of therapeutic cells. The immunomodulatory properties of mesenchymal stromal/stem cells (MSCs) from the foreskin (FSK-MSCs) are being evaluated in cell-based therapy for degenerative, inflammatory and autoimmune disorders. Within the injured/inflamed [...] [Read more](#).

(This article belongs to the Special Issue Mesenchymal Stromal Cell-Derived Secretome for Immunomodulation and Tissue Remodelling)

[► Show Figures](#)

Open Access Review



## Calorimetric Investigation of the Relaxation Phenomena in Amorphous Lyophilized Solids

by Sebastian Groß, Tim Menzen and Gerhard Winter

Pharmaceutics 2021, 13(10), 1735; <https://doi.org/10.3390/pharmaceutics13101735> - 19 Oct 2021

Viewed by 168

**Abstract** Studying the thermal history and relaxation of solid amorphous drug product matrices by calorimetry is a well-known approach, particularly in the context of correlating the matrix parameters with the long-term stability of freeze-dried protein drug products. Such calorimetric investigations are even more relevant [...] [Read more](#).

(This article belongs to the Special Issue New Trends in Freeze-Drying of Pharmaceutical Products)

[► Show Figures](#)

Open Access Article



## A Novel Method for Predicting the Human Inherent Clearance and Its Application in the Study of the Pharmacokinetics and Drug–Drug Interaction between Azidothymidine and Fluconazole Mediated by UGT Enzyme

by Yawen Yuan, Jun Zhang, Boyu Fang, Xiaoqiang Xiang, Guo Ma, Shunguo Zhang, Bin Zhu and Welmin Cai

Pharmaceutics 2021, 13(10), 1734; <https://doi.org/10.3390/pharmaceutics13101734> - 19 Oct 2021

Viewed by 160

**Abstract** In order to improve the benefit–risk ratio of pharmacokinetic (PK) research in the early development of new drugs, *in silico* and *in vitro* methods were constructed and improved. Models of intrinsic clearance rate ( $CL_{int}$ ) were constructed based on the quantitative structure–activity [...] [Read more](#).

[► Show Figures](#)

Open Access Article



## Development of Multi-Compartment 3D-Printed Tablets Loaded with Self-Nanoemulsified Formulations of Various Drugs: A New Strategy for Personalized Medicine

by Tarek A. Ahmed, Raed I. Fellimban, Hossam H. Tajeib, Waleed Y. Rizg, Fuad H. Alnadiw, Hanadi A. Alotaibi, Nabil A. Alhakamy, Fathy I. Abd-Allah, Gamal A. Mohamed, Ahmed S. Zidan and Khalid M. El-Say

Pharmaceutics 2021, 13(10), 1733; <https://doi.org/10.3390/pharmaceutics13101733> - 19 Oct 2021

Viewed by 297

**Abstract** This work aimed to develop a three-dimensional printed (3DP) tablet containing glibenclamide (GLMP) and/or rosuvastatin (RSV) for treatment of dyslipidemia in patients with diabetes. Curcumin oil was extracted from the dried rhizomes of *Curcuma longa* and utilized to develop a self-nanoemulsifying drug delivery [...] [Read more](#).

(This article belongs to the Special Issue Oral Drug Delivery Systems Based on Lipid-Based Carriers)

[► Show Figures](#)

Open Access Article



## On the Biocompatibility and Teat Retention of In Situ Gelling Intramammary Formulations: Cattle Mastitis Prevention and Treatment

by Sushila Bhattaral, Dhayaneethie Perumat, Michael J. Rathbone, Craig R. Bunt and Rald G. Alany

Pharmaceutics 2021, 13(10), 1732; <https://doi.org/10.3390/pharmaceutics13101732> - 19 Oct 2021

Viewed by 131

**Abstract** Treatment and prevention of cattle mastitis remains a formidable challenge due to the anatomical and physiological constraints of the cow udder. In this study, we investigated polymeric excipients and solvents that can form, (when combined) novel, non-toxic and biocompatible in situ gelling formulations [...] [Read more](#).

(This article belongs to the Special Issue *Advances In Veterinary Medicines and Vaccines*)

[► Show Figures](#)

Open Access Communication



## Pleiotropic Effects of Atorvastatin Result in a Downregulation of the Carboxypeptidase U System (CPU, TAFI, CPB2) in a Mouse Model of Advanced Atherosclerosis

by Karen Claesen, Lynn Roth, Joachim C. Mertens, Karlijn Hermans, Yani Sim and Dirk Hendriks

Pharmaceutics 2021, 13(10), 1731; <https://doi.org/10.3390/pharmaceutics13101731> - 19 Oct 2021

Viewed by 129

**Abstract** Statins (hydroxymethyl-glutaryl-CoA-reductase inhibitors) lower procarboxypeptidase U (proCPU, TAFI, proCPB2). However, it is challenging to prove whether this is a lipid or non-lipid-related pleiotropic effect, since statin treatment decreases cholesterol levels in humans. In apolipoprotein E-deficient mice with a heterozygous mutation in the floricillin-1 [...] [Read more](#).

(This article belongs to the Special Issue *Pleiotropic Effects of Statins: Developing New Therapeutic Approaches to Human Diseases*)

[► Show Figures](#)

Open Access Article



## Cellular Toxicity Mechanisms and the Role of Autophagy in Pt(IV) Prodrug-Loaded Ultrasmall Iron Oxide Nanoparticles Used for Enhanced Drug Delivery

by L. Gutiérrez-Romero, L. Rivas-García, C. Sánchez-González, J. Llopis, E. Blanco and M. Montes-Bayón

Pharmaceutics 2021, 13(10), 1730; <https://doi.org/10.3390/pharmaceutics13101730> - 19 Oct 2021

Viewed by 224

**Abstract** Ultrasmall iron oxide nanoparticles (<10 nm) were loaded with cis-diamminetetrachloroplatinum (IV), a cisplatin (II) prodrug, and used as an efficient nanodelivery system in cell models. To gain further insight into their behavior in ovarian cancer cells, the level of cellular incorporation as well [...] [Read more](#).

(This article belongs to the Special Issue *New Trends in Therapy: From Natural Products to Nanomedicine*)

[► Show Figures](#)

Open Access Article



## Quantification of Fluid Volume and Distribution in the Paediatric Colon via Magnetic Resonance Imaging

by Jan Goelen, Benoni Alexander, Haren Eranga Wijesinghe, Emily Evans, Gopal Pawar, Richard D. Horniblow and Hannah K. Batchelor

Pharmaceutics 2021, 13(10), 1729; <https://doi.org/10.3390/pharmaceutics13101729> - 19 Oct 2021

Viewed by 211

**Abstract** Previous studies have used magnetic resonance imaging (MRI) to quantify the fluid in the stomach and small intestine of children, and the stomach, small intestine and colon of adults. This is the first study to quantify fluid volumes and distribution using MRI in [...] [Read more](#).

(This article belongs to the Special Issue *New Developments in Pediatric Drug Formulations*)

[► Show Figures](#)

Open Access Article

## Optimization and Development of Selective Histone Deacetylase Inhibitor (MPT0B291)-Loaded Albumin Nanoparticles for Anticancer Therapy

by Athika Darumas Putri, Pal-Shan Chen, Yu-Lin Su, Jia-Pei Lin, Jing-Ping Liou and Chien-Ming Hsieh  
*Pharmaceutics* 2021, 13(10), 1723. <https://doi.org/10.3390/pharmaceutics13101723> - 19 Oct 2021

Viewed by 227

**Abstract** Histone deacetylase (HDAC) inhibitors have emerged as a new class of antitumor agent for various types of tumors. MPT0B291, a novel selective inhibitor of HDAC6, demonstrated significant antiproliferative activity in various human cancer cell types. However, MPT0B291 has very low water solubility, which [...] [Read more](#).

(This article belongs to the Special Issue Polymers Enhancing Bioavailability in Drug Delivery)

[► Show Figures](#)

Open Access Article

## Development, Evaluation, and Molecular Docking of Oral Dissolving Film of Atenolol

by Karina Citra Rani, Nani Parfati, Ni Luh Dewi Aryani, Agnes Nuniek Winantari, Endang Wahyu Fitriani, Aditya Trias Pradana, Rolsah Nawatla, Astridani Rizky Putranti, Florencia Irina, Florentia Angelica, Cintya Yohanes and Christina Avanti

*Pharmaceutics* 2021, 13(10), 1727. <https://doi.org/10.3390/pharmaceutics13101727> - 19 Oct 2021

Viewed by 263

**Abstract** The development of oral dissolving film (ODF) of atenolol is an attempt to enhance convenience and compliance for geriatric patients suffering from hypertension. Film former is the most essential component in ODF that determines the physical characteristic and drug release. In this study, [...] [Read more](#).

(This article belongs to the Special Issue ODX Formulations for Drug Delivery and Other Approaches to Overcome Swallowing Problems)

[► Show Figures](#)

Open Access Article

## Gold-Decorated Platinum and Palladium Nanoparticles as Modern Nanocomplexes to Improve the Effectiveness of Simulated Anticancer Proton Therapy

by Bartosz Kiebowski, Małgorzata Stec, Joanna Depoluch, Adrianna Galuszka, Anna Pajor-Swierzy, Jarek Baran and Magdalena Parilnska-Viojtan

*Pharmaceutics* 2021, 13(10), 1726. <https://doi.org/10.3390/pharmaceutics13101726> - 18 Oct 2021

Viewed by 189

**Abstract** Noble metal nanoparticles, such as gold (Au NPs), platinum (Pt NPs), or palladium (Pd NPs), due to their highly developed surface, stability and radiosensitizing properties, can be applied to support proton therapy (PT) of cancer. In this paper, we investigated the potential of [...] [Read more](#).

(This article belongs to the Special Issue Metal-Based Nanoparticles: New Insights into Cancer Diagnosis and Therapy)

[► Show Figures](#)

Open Access Article

## Deaggregation and Crystallization Inhibition by Small Amount of Polymer Addition for a Co-Amorphous Curcumin-Magnolol System

by Jiawei Han, Luyuan Li, Meiling Su, Wei Heng, Yuanfeng Wei, Yuan Gao and Shuai Qian

*Pharmaceutics* 2021, 13(10), 1725. <https://doi.org/10.3390/pharmaceutics13101725> - 18 Oct 2021

Viewed by 162

**Abstract** Different from previously reported co-amorphous systems, a co-amorphous curcumin-magnolol (CUR-MAG CM) system, as compared with its crystalline counterparts, exhibited decreased dissolution due to its aggregation during dissolution. The main purpose of the present study is to deaggregate CUR-MAG CM to optimize drug dissolution [...] [Read more](#).

[► Show Figures](#)